JSP Pharmaceutical Manufacturing (Thailand) Public (JSP) Fundamentals 2026 — P/E 13.7x, Revenue Analysis | SniperIQ
JSP Pharmaceutical Manufacturing (Thailand) Public (JSP) is a TH-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of ฿831M, trading at ฿1.75 on the SET. This SniperIQ fundamentals page covers JSP Pharmaceutical Manufacturing (Thailand) Public's valuation (P/E 13.7x, P/B 0.9x), profitability (net margin 6.2%), revenue (฿1.0B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is JSP Pharmaceutical Manufacturing (Thailand) Public's market cap?
JSP Pharmaceutical Manufacturing (Thailand) Public (JSP) has a market capitalization of approximately ฿831M, trading at ฿1.75 on the SET. Market cap moves with the live share price.
What is JSP Pharmaceutical Manufacturing (Thailand) Public's P/E ratio?
JSP Pharmaceutical Manufacturing (Thailand) Public's trailing twelve-month P/E ratio is 13.7x, with a price-to-book (P/B) of 0.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is JSP Pharmaceutical Manufacturing (Thailand) Public?
JSP Pharmaceutical Manufacturing (Thailand) Public runs a net profit margin of 6.2%, a gross margin of 39.8%, and an operating margin of 8.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does JSP Pharmaceutical Manufacturing (Thailand) Public generate?
JSP Pharmaceutical Manufacturing (Thailand) Public reported revenue of ฿1.0B for fiscal year 2025, with net income of ฿68M and earnings per share (EPS) of 0.14. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does JSP Pharmaceutical Manufacturing (Thailand) Public pay a dividend?
JSP Pharmaceutical Manufacturing (Thailand) Public offers a trailing dividend yield of about 5.7%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is JSP Pharmaceutical Manufacturing (Thailand) Public financially healthy?
JSP Pharmaceutical Manufacturing (Thailand) Public carries a debt-to-equity ratio of 0.44x and a current ratio of 1.33x, with a market beta of 0.40. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is JSP Pharmaceutical Manufacturing (Thailand) Public a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For JSP Pharmaceutical Manufacturing (Thailand) Public (JSP) the key facts are: market cap ฿831M, P/E 13.7x, revenue ฿1.0B, 52-week range 1.56-2.16. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track JSP Pharmaceutical Manufacturing (Thailand) Public's full fundamentals live
Get JSP Pharmaceutical Manufacturing (Thailand) Public's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.